GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » COGS-to-Revenue

Alzinova AB (OSTO:ALZ) COGS-to-Revenue : -60.56 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Alzinova AB COGS-to-Revenue?

Alzinova AB's Cost of Goods Sold for the three months ended in Mar. 2025 was kr-6.00 Mil. Its Revenue for the three months ended in Mar. 2025 was kr0.10 Mil.

Alzinova AB's COGS to Revenue for the three months ended in Mar. 2025 was -60.56.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Alzinova AB's Gross Margin % for the three months ended in Mar. 2025 was 6,155.56%.


Alzinova AB COGS-to-Revenue Historical Data

The historical data trend for Alzinova AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB COGS-to-Revenue Chart

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - - - -

Alzinova AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -94.10 - - - -60.56

Alzinova AB COGS-to-Revenue Calculation

Alzinova AB's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-16.781 / 0
=

Alzinova AB's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-5.995 / 0.099
=-60.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzinova AB  (OSTO:ALZ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Alzinova AB's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - -5.995 / 0.099
=6,155.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Alzinova AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alzinova AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzinova AB Business Description

Traded in Other Exchanges
Address
Pepparedsleden 1, Molndal, SWE, SE-431 83
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB Headlines

No Headlines